fdaMalaria: Developing Drugs for TreatmentOctober 31, 2025Read more →fdaInnovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small PopulationsOctober 31, 2025Read more →fdaPostapproval Methods to Capture Safety and Efficacy Data for Cell and Gene Therapy ProductsOctober 31, 2025Read more →fdaExpedited Programs for Regenerative Medicine Therapies for Serious ConditionsOctober 31, 2025Read more →fdaComputer Software Assurance for Production and Quality System SoftwareOctober 31, 2025Read more →fdaCVM GFI #299 -Dual Labeling for Fully Approved and Conditionally Approved New Animal Drugs with a New World Screwworm-Related IndicationOctober 31, 2025Read more →← Prev12345678910111213141516171819202122232425262728293031323334353637383940414243444546474849505152535455565758Next →
fdaInnovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small PopulationsOctober 31, 2025Read more →
fdaPostapproval Methods to Capture Safety and Efficacy Data for Cell and Gene Therapy ProductsOctober 31, 2025Read more →
fdaExpedited Programs for Regenerative Medicine Therapies for Serious ConditionsOctober 31, 2025Read more →
fdaCVM GFI #299 -Dual Labeling for Fully Approved and Conditionally Approved New Animal Drugs with a New World Screwworm-Related IndicationOctober 31, 2025Read more →
